Yet Another Value Podcast cover image

Caligan Partners' Dave Johnson on MorphoSys' $MOR change from royalty play to traditional biotech

Yet Another Value Podcast

CHAPTER

Pelobressev's Confidence Interval Is Higher Than the Other Drug

Pelobressev has improved efficacy and no increased toxicity. The lower, to me, the lower bound of the confidence interval on it is actually higher than that for other drug. We're going to increase our enrollment from 300 to 400 patients to make sure that we have the highest degree of success in that symptom score reduction. And again, you can tell me if I'm putting words in your team, we're more positive.

00:00
Transcript
Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner